scholarly journals Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain

2020 ◽  
Vol Volume 12 ◽  
pp. 253-264
Author(s):  
Josep-Maria Ribera Santasusana ◽  
Alejandra de Andrés Saldaña ◽  
Nuria García-Muñoz ◽  
Joana Gostkorzewicz ◽  
Diana Martínez Llinàs ◽  
...  
Keyword(s):  
Young Adults ◽  
Cost Effectiveness ◽  
Acute Lymphoblastic Leukaemia ◽  
B Cell ◽  
Lymphoblastic Leukaemia ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis ◽  
Children And Young Adults

Screening Adolescents and Young Adults for HIV in the United States: A Cost-Effectiveness Analysis

2017 ◽  
Vol 60 (2) ◽  
pp. S18
Author(s):  
Anne Neilan ◽  
Richard Dunville ◽  
M. Cheryl Banez Ocfemia ◽  
Joshua Salomon ◽  
Jordan Francke ◽  
...  
Keyword(s):  
United States ◽  
Young Adults ◽  
Cost Effectiveness ◽  
The United States ◽  
Cost Effectiveness Analysis ◽  
Adolescents And Young Adults ◽  
Effectiveness Analysis

Quality of life Evaluation in patients receiving Steroids (the QuESt tool): initial development in children and young people with acute lymphoblastic leukaemia

2015 ◽  
Vol 101 (3) ◽  
pp. 241-246 ◽  
Author(s):  
M Adams ◽  
M Robling ◽  
J Grainger ◽  
J Tomlins ◽  
A Johnson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Young Adults ◽  
Acute Lymphoblastic Leukaemia ◽  
Family Relationships ◽  
Lymphoblastic Leukaemia ◽  
Cognitive Interviewing ◽  
Initial Development ◽  
Children And Young Adults ◽  
The Impact

BackgroundThe powerful cytotoxic and immunomodulatory effects of corticosteroids are an important element of the success that has been achieved in the treatment of acute lymphoblastic leukaemia (ALL). In addition to physical side effects, corticosteroids can adversely influence behaviour, cognitive function and mood leading to significantly impaired quality of life (QoL). A number of tools exist for assessing QoL, but none of these specifically examines changes attributable to steroids.MethodsChildren and young adults aged 8–24 years and parents of children receiving maintenance therapy for ALL from four UK centres were invited to participate. The study comprised three stages carried out over 2 years: (1) focus groups and interviews where participants were asked to describe their experiences of dexamethasone; (2) analysis of questionnaires sent to healthcare professionals and patients to evaluate the importance and relevance of the questions; and (3) cognitive interviewing.ResultsInterpretative phenomenological analysis of focus group and interview transcripts identified that dexamethasone adversely influenced behaviour, appetite, body image, mood and family relationships. 157 electronic survey responses were analysed leading to further item development. Cognitive interviewing confirmed face validity and internal consistency. QuESt comprises 28 questions within four domains and has three age-specific versions.ConclusionsQuESt is the first treatment-specific QoL measure for children and young adults receiving corticosteroids. It can be completed in 10–15 min by children aged ≥8 years. Further validity and reliability testing will be undertaken. Although the initial application is for ALL, QuESt may also be a valuable tool for understanding the impact of corticosteroids in other paediatric conditions.

Sign in / Sign up

Export Citation Format

Share Document